Amylyx discontinues AMX0035 program for PSP after Phase 2b miss

Amylyx Pharmaceuticals, Inc.

AMX0035 failed to show differences vs placebo on primary or secondary outcomes at Week 24.
Company will discontinue Phase 2b trial and open-label extension; will not proceed to Phase 3.
Safety data consistent with prior AMX0035 studies.
ORION program for progressive supranuclear palsy (PSP) is discontinued entirely.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.